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Abstract 
 
Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In 
both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events. However, 
VKA therapy is associated with challenges relating to dose maintenance, the need to monitor anticoagulation, and bleeding risks. 
The non-vitamin K oral anticoagulants (NOACs) are becoming accepted as a clear alternative to VKA therapy for both AF and VTE 
management. The aim of this paper was to review contemporary evidence on the safety of NOACs in both conditions. A 
comprehensive literature review was conducted to explore key safety issues and expert consensus was achieved from eight 
professionals specialised in AF and VTE care. Consensus-based statements were formulated where available evidence was weak 
or contradictory. The expert statements in this paper form a key overview of the safety of NOACs compared with VKA therapy, and 
the comparative safety of different NOACs. It is apparent that a detailed patient work-up is required in order to identify and manage 
individual risk factors for bleeding and thrombosis prior to NOAC therapy. Additional measures, such as dose reductions, may also 
be used to maintain the safety of NOACs in practice.   
 
Keywords: oral anticoagulants, pulmonary embolism, deep vein thrombosis, atrial fibrillation, expert consensus 
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Introduction 
 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an incidence of 0.85–4.1 per 1000 person-years, depending on 
the cohort studied (1–3). Morbidity and mortality are associated with AF, which particularly increases stroke risk five-fold. 
Approximately 20% of ischaemic strokes are directly attributable to AF (4).  
 
Venous thromboembolism (VTE) is a term used to describe pulmonary embolism (PE) and deep vein thrombosis (DVT) or both. It 
is estimated that VTE affects over 1 million people in Europe annually (5), with a 21.6% all-cause mortality after one year of 
diagnosis (6). Without anticoagulation therapy, recurrence of VTE occurs at a rate of 12.9% within the first year of diagnosis (7). 
The rate of recurrence with anticoagulation therapy peaks at 11.1 per 100 person-years within 180 days following the first event, 
falling to 8.1 per 100 person years between 181–365 days post-event (6). 
 
For both AF and VTE, the use of long-term anticoagulation strategies is recommended to prevent stroke in AF patients and/or 
thromboembolic events in both. The use of vitamin K antagonists (VKAs), including warfarin, is a common approach to 
anticoagulation, but is associated with a number of practical challenges, including the unpredictable nature of anticoagulation 
achieved with the drug on a patient-by-patient basis, numerous food and dietary interactions, and the need for constant 
anticoagulation monitoring (8,9). Optimal anticoagulation with VKA therapy in AF and VTE is defined as an international normalised 
ratio (INR) of 2–3 (10). Deviation from this range, with poor anticoagulation control, has the potential to decrease the efficacy or 
increase the bleeding risk of the drug (11–14). 
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The non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as viable alternatives to VKA therapy in patients with AF 
or VTE. Four drugs are currently approved for these indications in Europe: dabigatran, apixaban, rivaroxaban, and edoxaban. 
Dabigatran is a direct thrombin inhibitor (15), while the other NOACs target Factor Xa (16–18). Phase III trials of the NOACs 
compared to VKA therapy demonstrate non-inferiority, and in some cases superiority, of these agents for reducing the risk of 
stroke/thromboembolic events in AF patients and in reducing the risk of recurrence in VTE patients. All NOACs have also been 
shown to be non-inferior or superior to VKAs for key safety outcomes, including the risk of bleeding. These agents have a 
predictable dosing profile, fewer drug and dietary interactions than VKAs, and do not require anticoagulation monitoring (19–21).  
 
However, the safety profile associated with anticoagulant use varies within these populations. Patients with either AF or VTE  are 
heterogeneous in nature, and characterised by multiple risk factors for bleeding or thromboembolism. Factors such as age, rena l 
function, body weight, frailty, and the presence of comorbid disease may influence the response to NOACs and the subsequent 
safety of these agents. As a result, there is a growing need for appreciation of the safety features of NOACs to be comprehensively 
reviewed, in order to direct or tailor therapy in specific patient sub-populations and in specific care contexts (22,23).  
 
 
Aim 
 
The aim of this paper was to provide an overview of the current evidence base in order to characterise how NOACs can be used 
safely within the clinical setting. To meet this aim, the following objectives were met: 
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 Comparison of safety outcomes for NOACs and alternative anticoagulants 
 Evaluation of safety in specific clinical scenarios and patient groups 
 Consideration of NOAC dosing and practical administration. 
 
 
Methods 
 
A comprehensive, systematic literature search was completed to provide an overview of the safety of NOACs in clinical practice. 
This search was conducted using multiple online databases, including papers published up to the 31st March 2017. Primary data 
sets were used for analysis wherever possible, while the summary of product characteristics (SmPC) for each NOAC was 
consulted to ensure accurate dosing information. Once the final data set was identified, these papers were critically appraised, and 
key evidence was extracted in order to provide a synthesis of safety data.  
 
This report was composed in collaboration with an international panel of eight experts in the field of AF or VTE (inclusive of two 
chairpersons) in order to ensure the clinical relevance of all expert statements. A consensus process was employed based on a 
modified Delphi technique, wherein all experts were asked to contribute their clinical expertise in defining key clinical que stions, as 
well as in the generation of expert statements. This strategy took place in a series of ‘rounds’, consistent with the iterative nature of 
the process. Specifically, once the key clinical topics were identified, all experts were asked to complete questionnaires and 
indicate their agreement with evidence statements. Based on the level of agreement noted for all experts these statements were 
revised and the process was repeated, if necessary. This was continued until a consensus was achieved, defined as agreement of 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
at least 70% of the experts. Where there was continued disagreement among the experts, the chairpersons had a final say over the 
direction of any expert statements. 
 
For each expert statement, the strength of available research evidence is presented, based on the criteria noted in table 1. Level I 
evidence comprises meta-analyses or RCTs and high-quality RCTs. Level II evidence comprises quasi-experimental studies and 
controlled studies (non-randomised). Level III evidence comprises descriptive studies (e.g. comparative, correlation or case-control 
methodologies). Finally, Level IV evidence suggests that there is a lack of formal research in this area, and that expert opinions or 
reports form the basis for this level of evidence (24).  
 
Following determination of the existing level of support, for each expert statement the strength of the statement (SOS) was 
determined. The SOS is a marker for the overall degree to which the evidence supports the assertion of the expert statement. Two 
categories were used for the sake of simplicity: strong and weak statements. Strong statements included more definitive wording 
(i.e., “it is advised that” or “strongly advised that”), while weak statements were represented in a less authoritative manner (i.e., 
“should be”). When consensus was used to achieve the statement, the percentage agreement was recorded along with the SOS, to 
highlight the level of agreement between experts. Where consensus was not considered necessary, based on the quality o f 
available data, the “% agreement” component is absent from the expert statement.  
 
 
Results and expert statements 
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The results of the combined literature search and consensus process are presented according to three categories: patient safe ty 
outcomes; specific patient groups; and practical issues in prescribing. For each of these categories the statements are presented, 
with a supporting summary of the available evidence. Statements where consensus was required are clearly noted. In total, 44 
statements were formulated, 22 of which were based on expert consensus due to a lack of available evidence or conflicting data.  
 
 
Patient safety outcomes 
 
This paper focused on five main patient safety outcomes: major or clinically relevant non-major (CRNM) bleeding; intracranial 
bleeding; gastrointestinal bleeding; bleeding mortality; and cardiovascular mortality. Statements are presented in table 2.  
 
Major or CRNM bleeding 
 
Phase III trials in patients with AF (25–28) demonstrate that all NOACs are associated with similar or reduced risks of major or 
CRNM bleeding compared to warfarin therapy. For dabigatran, there was a dose-dependent effect on major bleeding, with 110 mg 
twice daily associated with a statistically significantly lower rate of bleeding compared to warfarin (p=0.003), but  comparable 
bleeding rates with 150 mg twice-daily dabigatran and warfarin. For rivaroxaban, the rate of major bleeding was comparable to that 
seen with warfarin (p=0.35). Apixaban was associated with a statistically significant reduction in major bleeding  compared to 
warfarin (p<0.001). Finally, edoxaban was associated with a significant reduction in all major bleeding compared to warfarin, 
regardless of the edoxaban dose (p<0.001).  
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For the phase III trials of NOACs versus VKA therapy in patients with VTE, the major safety outcome was CRNM bleeding or 
composite bleeding outcomes (29–33). The data from these trials suggest that all NOACs are at least non-inferior to warfarin for 
this safety outcome. For dabigatran 110 mg twice daily, a composite endpoint of major and CRNM bleeding suggested a lower rate 
of bleeding with dabigatran, although statistical significance was not reported. Similarly, the rate of major bleeding wa s reduced by 
69% with apixaban compared to warfarin, and the rate of major or CRNM bleeding was significantly reduced. There was no 
significant difference between the rates of first major or CRNM bleeding for rivaroxaban compared to warfarin in either the 
EINSTEIN-DVT or EINSTEIN-PE studies. Edoxaban was shown to be superior to warfarin for CRNM bleeding in a statistical ly 
significant manner (p=0.004).  
 
It has been recommended that major or CRNM bleeding should be considered an important factor in guiding NOAC selection 
versus VKA therapy (34). However, other factors need to be taken into account to ensure patient safety. Expert consensus 
supported the identification of modifiable risk factors prior to anticoagulant use. However, bleeding risk is highly dynamic, and 
hence regular reassessment of modifiable bleeding risk factors is needed in patients ‘flagged up’ for review, with suitable follow-up 
(35). 
 
 
Intracranial bleeding 
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The risk of intracranial bleeding with anticoagulation therapy is important, as it is strongly associated with poor patient outcomes. In 
phase III trials with AF patients, there was a significant reduction in intracranial bleeding associated with NOAC use compared to 
warfarin. For dabigatran, both 110 mg and 150 mg twice-daily doses were associated with statistically significant reductions in 
intracranial bleeding compared to warfarin (p<0.001 for both). Similarly, intracranial bleeding was significantly lower with 
rivaroxaban compared to warfarin (p=0.02). Apixaban was associated with a significant reduction in intracranial bleeding compared 
to warfarin. The investigation of intracranial bleeding rates in patients treated with NOACs for VTE demonstrated a significantly 
lower rate of intracranial bleeding associated with NOAC therapy compared to warfarin therapy.   
 
The evidence suggests that NOACs are likely to be preferable to VKA therapy for the prevention of intracranial bleeds . Important 
considerations pertain as to when best to restart OAC after a presentation with an intracranial bleed, as such patients were 
excluded from clinical trials (36). 
 
 
Gastrointestinal bleeding 
 
A meta-analysis of NOAC studies found that the NOACs are associated with a higher rate of gastrointestinal bleeding than warfarin 
therapy, with similar rates observed with low-dose NOAC regimens and warfarin use (37). However, the rates of gastrointestinal 
bleeding varied and were comparable with apixaban and warfarin (0.76% vs 0.86%, HR 0.89, 95% CI 0.70–1.15, p=0.37). The rate 
of gastrointestinal bleeding with the high-dose edoxaban regimen (60 mg) was not statistically different to that seen with warfarin 
therapy. In the VTE trials, the rate of gastrointestinal bleeding was similar with the NOACs compared to warfarin, with the e xception 
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of apixaban, for which the rate was significantly lower. A meta-analysis of phase III trial data suggests that the risk of major 
gastrointestinal bleeding did not differ significantly between the NOACs and warfarin (38). Consequently, the use of either NOACs 
or VKA therapy should prompt a risk assessment for gastrointestinal bleeding in eligible patients to ensure safety.  
 
 
Fatal bleeding 
 
Although bleeding events were extensively documented in phase III trials, the incidence of fatal bleeding was not consistentl y noted 
in the RE-LY or ARISTOTLE trials (life-threatening bleeding in combination with major bleeding was here used as an outcome). 
Edoxaban (at both doses) and rivaroxaban were associated with a reduction in fatal bleeding events compared to warfarin. Data on 
dabigatran and apixaban are available from additional analyses, although the statistical significance of these events is unce rtain. 
Fatal bleeding in VTE studies was generally infrequent, and none of the studies showed a significant difference between fatal  
bleeding rates for any NOAC compared to warfarin. A meta-analysis (39) of randomised trials of AF and VTE patients receiving 
NOAC therapy showed that the rate of fatal bleeding events was generally lower with the NOACs, although the effect was more 
pronounced in AF patients.  
 
Despite the benefits of NOACs in reducing fatal bleeding compared with VKA therapy, expert consensus determined that fatal 
bleeding risk alone was not sufficient to justify the use of NOACs over VKA, as a multifactorial analysis of bleeding and thrombosis 
risk should be used to guide treatment choice.  
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Cardiovascular mortality 
 
The phase III NOAC trials in patients with AF explored cardiovascular outcomes of the NOACs compared to warfarin therapy. Onl y 
the ENGAGE AF-TIMI 48 trial (edoxaban) demonstrated a statistically significant reduction in cardiovascular mortality associated 
with edoxaban compared to warfarin. A non-significant reduction in cardiovascular deaths was observed in the ROCKET-AF trial 
with rivaroxaban compared to warfarin. Neither the RE-LY nor ARISTOTLE trials provide detailed data on cardiovascular mortality. 
However, the RE-LY study demonstrated a lower level of cardiovascular mortality with the higher dose of dabigatran compared to 
warfarin, while the ARISTOTLE study reported comparable mortality due to cardiovascular causes in both treatment groups (1.80% 
per year with apixaban and 2.02% per year with warfarin) . Cardiovascular mortality has not been explored in detail for patients with 
VTE in phase III NOAC trials, largely due to the low rate of cardiovascular deaths seen with either NOACs or warfarin in these 
trials. In all phase III VTE trials cardiovascular mortality was low with NOACs and there is no discernible difference betwee n the 
findings for individual NOACs.  
 
Based on these data, expert consensus is that cardiovascular risk alone does not justify NOAC use over VKA use in either AF or 
VTE patients, but cardiovascular risk factor identification and management should be prompted prior to either therapy.  
 
 
Specific patient groups 
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Specific patient groups were selected on the basis that they may be associated with alterations in the safety profile of anti coagulant 
use in both AF and VTE. Expert statements for the defined patient groups are presented in table 3. 
 
 
Elderly and fragile patients 
 
Patients aged over 75 years are at overall high risk of stroke irrespective of the presence of AF (40), and have been shown to have 
an increased risk of adverse events associated with AF or VTE, as well as with the anticoagulation strategy used for these 
indications. The efficacy and safety of the NOACs in older patients has been noted in trial subgroup analyses for both AF and VTE 
patients, suggesting that both outcomes are comparable to or better than those seen with warfarin therapy.   
 
For patients with VTE, trial data suggest that the safety of each NOAC is preserved in older patient subgroups. However, only a 
small proportion of patients were aged ≥75 years in these trials, and the presence of comorbidities in trial populations may be lower 
than that seen in clinical practice populations (41). Only rivaroxaban and edoxaban trials have reported specific analyses of the 
fragile population. An analysis of the EINSTEIN-PE and EINSTEIN-DVT trials defined fragile patients as those who were elderly, 
had moderate or severe renal impairment, or low body weight. According to this definition, the rate of bleeding was higher in fragile 
patients compared to the general study population.  
 
Rivaroxaban demonstrated superior safety compared to standard therapy for fragile patients, with a significant reduction in major 
bleeding (HR, 0.27; 95% CI, 0.13–0.54; P= 0.011), which was not the case in non-fragile patients (42). In the HOKUSAI-VTE trial 
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(29), 1,421 patients were classified as fragile (CrCl 30–50 mL/min, age ≥75 years of age, or body weight ≤50 kg). Comparable 
rates of clinically relevant bleeding were observed in fragile and non-fragile patients, showing that edoxaban maintained superiority 
for safety compared to standard therapy. An analysis of dose-reduced edoxaban (30 mg) in VTE patients has shown comparable 
safety and efficacy compared with the 60 mg dose, but improved safety compared with warfarin (43). 
 
For elderly patients, it is recommended that NOACs should be considered as viable alternatives to VKA therapy. Age alone should 
not be universally considered a sufficient justification for dose reduction of NOACs, however, and specific guidelines for dose 
reduction are reported in the specific SmPCs. Dose reductions to maintain safety should be specifically based on published 
guidance. However, real world data on elderly patients with AF are needed (44). 
 
 
Patients with active cancer 
 
Cancer is known to be a hypercoagulable state, increasing the risk of VTE in patients (45,46). It is estimated that patients with 
active cancer have a 4 to 8-fold increased risk of VTE compared to the general population (47,48). Patients with AF and active 
cancer have an increased risk of bleeding and thrombosis compared to the general AF population (49). 
 
A systematic review and meta-analysis of data for VTE management in cancer patients suggested that NOACs may be beneficial 
compared to warfarin, although these findings did not approach statistical significance due to small numbers of patients in these 
trials (50). Furthermore, data comparing NOACs with LMWH for the prevention of thrombosis are minimal. The data comparing 
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NOACs to warfarin in patients with AF and cancer are also limited by exclusion criteria in phase III trials, includ ing life expectancy 
of patients. It can be expected that drug-drug interactions (including common chemotherapy regimens), bleeding risk and 
thrombosis risk all contribute towards the suitability of NOACs versus warfarin in this group. Therefore, pending fu rther data, 
patients with active cancer should be thoroughly assessed to determine their bleeding risk and risk of VTE or stroke/SEE. 
However, given that warfarin is the standard therapy in patients with AF, the presence of cancer in AF patients is not, at  the 
moment, a contraindication to the use of a NOAC. 
 
Overall, expert consensus noted that VTE guidelines should be followed, with NOACs only considered when patients cannot 
tolerate LMWH, with NOACs representing alternatives to VKA therapy. In patients with cancer bleeding risk factors and drug-drug 
interactions should be carefully considered when selecting NOACs, while dose reductions are recommended in patients with 
impaired renal function, low body weight and/or advancing age. However, recent data from the Hokusai VTE cancer study (51) 
found that the combination of LMWH (minimum of 5 days) followed by edoxaban 60 mg once daily was non-inferior to the use of 
subcutaneous dalteparin (200 IU per kg body weight for one month followed by 150 IU per kg body weight) in patients with cancer-
associated VTE (P=0.006). The primary outcome in this study was composite recurrent VTE or major bleeding during 12 months 
following randomisation: the lower rate of recurrent VTE with edoxaban (7.9% vs 11.3%) was offset by the higher rate of major  
bleeding with edoxaban (6.9% vs 4.0%). Therefore, edoxaban may be considered as an alternative to LMWH in patients with 
cancer-associated VTE and optimisation of control of modifiable bleeding risk factors should be emphasised. 
 
 
Patients with renal impairment 
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Renal impairment is an independent risk factor for haemorrhage (52), potentially increasing the risk of adverse bleeding events in 
patients on oral anticoagulant therapy. VKA therapy is associated with a poor safety record in patients with renal impairment  (53), 
hence NOACs may be a good alternative to warfarin. However, the NOACs undergo renal clearance to varying degrees and 
therefore there is the potential for increased drug exposure in renal impairment.  
 
In AF patients, numerous analyses have been conducted on NOAC efficacy and safety based on renal function  (54). Data from the 
RE-LY trial showed that stroke/SEE rates were lower with dabigatran 150 mg twice daily compared to warfarin, regardless of renal  
function (55), but significant reductions in major bleeding were only seen in patients with CrCl ≥80 mL/min. In the ROCKET-AF trial, 
patients with CrCl 30–49 mL/min received a reduced dose of 15 mg once daily rivaroxaban, which was associated with comparable 
safety and efficacy outcomes to warfarin therapy and a lower rate of fatal bleeding (56). In the ARISTOTLE trial, apixaban was 
dose-reduced to 2.5 mg twice daily in patients with 2 or 3 risk factors (serum creatinine ≥1.5 mg/dL, age ≥80 years, or body weigh t 
≤60 kg) (57). Subgroup analyses showed that patients with CrCl 30–50 mL/min or lower, had a greater reduction in major bleeding 
with apixaban compared to warfarin. A recent analysis (58) of edoxaban versus warfarin in patients with CrCl ≤50 mL/min or >50 
mL/min showed that higher-dose edoxaban regimen (60 mg/30 mg) was associated with a lower bleeding rate compared to 
warfarin, regardless of CrCl. Furthermore, the net clinical benefit of highe r-dose edoxaban remained favourable compared to 
warfarin across all CrCl values (58). 
 
For VTE, a pooled analysis of the NOAC trials suggested that safety outcomes (clinically relevant bleeding) were consistent i n 
patients with and without renal impairment (defined as CrCl 30–50 mL/min) (59). However, in the AMPLIFY trial only 6% of patients 
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in the apixaban arm had a CrCl <50 mL/min (30). Similarly, in the Hokusai-VTE trial only 7% of patients had a CrCl of 30–50 
mL/min (29). Therefore, the generalisability of these findings to the practice VTE population may be limited. It is important to 
consider labelling recommendations in addition to trial data, however. For instance, rivaroxaban was used without dose adjustment 
in patients with renal impairment in the EINSTEIN trials, but now consideration of dose reduction is suggested in rivaroxaban 
labelling in this context. This applies to multiple aspects of pharmacological dosing, particularly as more data become available.  
 
There are sufficient data to suggest that renal impairment demands modification of NOAC doses in some settings and careful 
consideration of NOAC use. Published guidelines should be adhered to in this context.  
 
Other patient groups 
 
Obese patients may demonstrate alterations in NOAC  pharmacokinetics and exposure and have an increased risk of hypertension 
and cardiovascular disease compared to the non-obese population (60). However, limited data are available regarding NOAC 
therapy in obese patients (60). The RE-LY study noted a 20% decrease in trough concentrations of dabigatran in patients over 100 
kg in weight (25). However, dosing adjustments for obese patients are not currently recommended (55). Similarly, for rivaroxaban 
and apixaban no changes in dosing are recommended in obese patients, although the ARISTOTLE trial only stratified patients as 
weighing less than or greater than 60 kg, limiting the ability to draw conclusions regarding efficacy in obesity (26). Data on 
edoxaban suggest that dose adjustment based on obesity may not be warranted (61). Expert consensus recommends avoiding 
dose adjustments due to obesity. Patients with low body weight have been considered elsewhere in the literature (60) and current 
recommendations for dose reductions, based on product labels, should be adhered to in such patients.   
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Whether or not patients with a single stroke risk factor i.e. CHA2DS2-VASc = 1 (men) or 2 (women) require oral anticoagulation 
remains controversial. These patients are considered at low-risk for thrombotic events, but may still have preventable morbidity and 
mortality associated with stroke risk. These patients are under-represented in clinical trials but observational studies have 
suggested a net clinical benefit of NOACs versus aspirin (a treatment alternative that is not widely recommended) or no 
antithrombotic therapy in patients with one additional CHA2DS2-VASc stroke risk factor (excluding sex) (62–64). However, 
confounding factors may have influenced these findings, including variation in bleeding risk or disease severity in patients initiated 
on anticoagulation. Data from the SPORTIF trials suggest that patients with one additional stroke risk factor have a high rate of 
major adverse events (stroke/SEE and mortality), even when oral anticoagulation was used (65). Expert consensus agrees with 
published ESC guidelines, recommending anticoagulation in men with CHA2DS2-VASc = 1 and women with CHA2DS2-VASc = 2, 
depending on individual risk factors, 
 
Previous cerebral ischaemic events in patients with AF are associated with an increased risk of future events (66–68) but a highly 
relevant question is when to reinitiate OAC after presentation with an ischaemic stroke (69). Phase III NOAC trials found that 
patients with previous stroke/transient ischaemic attack (TIA) had a higher rate of stroke than patients without a history of 
stroke/TIA. Subgroup analyses of trials exploring the use of dabigatran, rivaroxaban and apixaban found similar efficacy and safety 
with these NOACs, regardless of stroke/TIA history (70–72). A meta-analysis of apixaban, dabigatran, and rivaroxaban found that 
NOACs were comparable to warfarin for the prevention of stroke/SEE in patients with a history of stroke/TIA, while the rate o f 
intracranial bleeding was lower with NOACs compared with warfarin in this subgroup (73). Edoxaban has also been shown to have 
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a lower rate of bleeding compared to warfarin for primary and secondary stroke prevention (74). Therefore, NOACs are 
recommended for use in patients with or without previous history of stroke/TIA. 
 
The bleeding risk of an individual patient is an important consideration prior to NOAC therapy, as all forms of anticoagulation may 
be associated with a risk of bleeding. Bleeding risk scores may be used to inform clinicians of the risk of haemorrhage in pa tients 
with AF. The appropriate use and misuse of bleeding risk scores has recently been discussed (35). The use of over-simplified 
bleeding risk scores (e.g. ORBIT, ATRIA) may result in many patients with a high bleeding risk not being identified appropriately 
(75). 
 
The HAS-BLED score has been shown to outperform alternative bleeding risk scores in real-world and trial patient populations and 
has practical advantages over other scoring systems (76,77), suggesting that it should be preferentially used in practice.  Since 
VKAs are most widely used worldwide, other scores that do not account for labile INR or poor TTR would perform suboptimally in 
predicting bleeding risk (78,79). However, other bleeding risk scores may play an important role in evaluating bleeding risk (major 
and clinically relevant non-major bleeding), and no preference is indicated in recent European guidelines. Therefore, the use of any 
bleeding risk score can be considered a means of flagging up high risk patients to be brought back for review and more careful 
follow-up, and for identifying modifiable risk factors for bleeding; the key issue is identifying these risk factors and addressing them, 
as appropriate. In the pursuit of individualised approaches to patient risk assessment and anticoagulant therapy, consideration of 
individual risk factors may be more important than general risk factor scores for justifying dose-reduced NOAC therapy (80). Expert 
consensus advises individual risk factor assessment and the use of bleeding scores to assist in this process.  
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Clinically relevant non-major bleeding poses a challenge to healthcare professionals and patients and is defined as bleeding that 
does not meet major bleeding criteria, but which requires healthcare intervention, contact with physicians, interruption of t he study 
drug, discomfort or impacts of activities of daily living. The findings of large clinical trials suggest NOACs have a similar level of 
safety for major and clinically relevant non-major bleeding compared with warfarin therapy. Therefore, pending further data, the 
same recommendations may apply to the use of NOACs with both types of bleeding as safety outcomes.  
 
Nuisance bleeding should also be recognised as a clinical problem, encompassing minor bleeding, which is often temporary, but 
which may prompt patient dissatisfaction and physician medication switching  (34,81). Nuisance bleeding may account for 
uncontrolled treatment interruptions initiated by the patient. These bleeding events may include gum bleeding or nosebleeds, and 
patients should be advised of strategies to minimise these events (e.g. , the use of soft toothbrushes, or of an electric razor when 
shaving). Ultimately, nuisance bleeding is not a sufficient justification for switching oral anticoagulants and modifiable risk factors 
should be addressed.   
 
Dual antiplatelet therapy is an important clinical challenge in NOAC use. The combination of AF and coronary artery disease (CAD) 
is common in the practice setting (82) and adds complexity to the management of AF patients due to the higher risk of mortality 
and the increased risk of bleeding noted with the use of anticoagulation and antiplatelet therapy (81). Combination therapy is often 
inappropriately prescribed in the setting of AF, and mostly in the presence of concomitant vascular disease, under the wrong belief 
that antiplatelet agents are the default best option in such patients  (83). It is estimated that the risk of bleeding increases roughly 
60–80% when combining anticoagulants with single antiplatelet therapy, and by at least 130% with dual antiplatelet therapy (84). 
Phase III trials failed to show any effect of previous myocardial infarction or the use of dual antiplatelet therapy on safet y outcomes 
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when comparing NOACs and VKA therapy for AF management. However, the PIONEER AF-PCI trial (85) showed that the use of 
reduced dose rivaroxaban plus dual antiplatelet therapy led to significantly reductions in bleeding compared to VKA therapy in 
combination with dual antiplatelet therapy. Furthermore, the REDUAL trial showed that dabigatran plus P2Y12 inhibitor therapy 
was associated with a lower bleeding risk post-PCI compared with combined warfarin, P2Y12 inhibitor and aspirin therapy (86).  
 
Recent guidance suggests that the use of dual antiplatelet therapy in combination with oral anticoagulation is required after  PCI 
and should be limited in duration to minimise excessive bleeding risks (81,87), although It may also be, based on the PIONEER-AF 
study, that the use of aspirin in the presence of 15 mg/day rivaroxaban may be safely omitted (85). However, this study was not 
powered to show any difference in efficacy, suggesting further data are needed to confirm this finding.  
 
There is no evidence to suggest that the benefits of prolonged antiplatelet therapy lead to clinical benefits, and NOAC monot herapy 
should be advised in patients with stable vascular disease (≥1 year after an acute coronary syndrome). Ultimately, the decision to 
combine NOACs and single or dual antiplatelet therapy should be based on a comprehensive evaluation of cardio-embolic risk, 
bleeding risk and athero-thrombotic risk. 
 
Incidental or unsuspected VTE can be defined as the detection of either DVT or PE during imaging studies for unrelated reasons 
(e.g., cancer staging) (88). Due to a lack of prospective interventional studies assessing the optimal management approach in 
incidental VTE, the benefit of anticoagulation and the selection of specific agents remain controversial. There is presently a lack of 
evidence to suggest any negative effects of therapeutic anticoagulation with NOACs in patients with incidental VTE, provided there 
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are no other contraindications to therapy. However, confirmation of the diagnosis should be sought prior to initiating treatment, 
where possible, in order to ensure that NOACs are used appropriately (89).  
 
 
Practical issues in prescribing 
 
There are instances where the practical use of NOACs may be associated with variations in patient safety, including the use of  
NOACs and reversal agents during acute bleeding, switching from VKA therapy to NOACs, and with or without a heparin lead-in for 
VTE management. The expert statements for practical issues of NOAC safety are presented in table 4.  
 
 
Managing acute bleeding 
 
One of the major sources of concern regarding broad uptake of the NOACs is the lack of specific reversal agents (90). Warfarin 
can be effectively monitored through INR determinations and the anticoagulant effects reversed, albeit slowly with vitamin K1 
administration (91). However, the short half-life of NOACs suggests that in most instances doctors need only to wait for bleeding to 
stop without the need for an antidote. The indications for when antidotes are needed should be clarified, without overreliance on 
these measures in cases of bleeding that is not severe or life-threatening.  
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Idarucizumab is the first specific reversal agent for NOACs to be approved, and irreversibly binds to dabigatran neutralising its 
activity (92). Its approval was based on the reduction in unbound dabigatran and the rapid normalisation of coagulation parameters 
in healthy volunteers in the context of emergency procedures and life-threatening or uncontrolled bleeding (93). Reassuring data 
are now also available from a phase III ‘real world’ study with this agent (94).  
 
Andexanet alfa, a recombinant modified human factor Xa decoy protein, is currently under investigation as a potential reversa l 
agent for factor Xa inhibitors (95). Ciraparantag is currently in clinical development, and may act as a universal reversal agent, 
based on its potential to bind edoxaban, rivaroxaban, apixaban and dabigatran, as well as heparins, in preclinical models (96). 
Reversal of edoxaban effects is also evident in the literature (97).  
 
Specific reversal agents should be used according to the protocol proposed by the International Society on Thrombosis and 
Haemostasis (98). A general approach to the management of bleeding patients has also been discussed in a recent white paper 
from the Anticoagulation Education Task Force (99). This should include discontinuation or delay of NOAC use in minor bleeding 
(bleeding that does not fulfil criteria for major or non-major clinically relevant bleeding), and fluid support, mechanical compression 
and transfusion in moderate or severe cases of bleeding (100). Non-specific reversal agents may also play a role in severe or life-
threatening bleeding events on NOACs, including PCC and rVIIa, although the evidence for the latter is weak (100). A graduated 
approach to bleeding is advised by the expert panel, reserving specific reversal agents for life-threatening or severe bleeding.  
 
 
Switching from VKA to NOACs 
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The potential for NOACs to essentially replace VKA therapy in eligible patients has led to important questions regard ing which 
patients should be switched to NOACs and how the transition process should be managed. The phase III clinical trials of NOACs 
do not explore this issue in depth, but provide an insight into the safety of NOACs when administered in patients who ha ve 
received previous VKA therapy or those who are VKA-naïve. For all of the AF trials, the efficacy and safety of NOACs was 
comparable in either VKA-experienced or naïve patients (25–28). 
 
Switching from VKA therapy to a NOAC is associated with minimal changes of the pharmacokinetics and pharmacodynamics of the 
NOACs. Recently it has been shown that the risk of bleeding is low during and in the short term following this transition (101). A 
randomised trial investigating the switch from warfarin to edoxaban found that edoxaban administered 24 hours after the last dose 
of warfarin was safe and well tolerated (102). Data from the Dresden NOAC registry suggested that, in 716 switched from VKA 
therapy to NOACs, the 30-day rate of cardiovascular events or major bleeding events was very low, regardless of INR testing prior 
to switching (103). 
 
The decision to switch to a NOAC from VKA therapy should be based on pragmatic decision-making, taking into account the 
available clinical evidence, the patient’s comorbidities and clinical status, and patient’s wishes. Once the decision to switch has 
been made, the process of switching is important to minimise time spent o ut of an effective anticoagulant state. According to the 
SmPC for each NOAC, switching may be directed based on the most recent INR value obtained while the patients end their VKA 
therapy. A NOAC should be started when the INR is ≤3 for rivaroxaban, ≤2.5 for edoxaban, and ≤2 for apixaban and dabigatran. It 
has been uniformly recommended in the EHRA Practical Guide that an INR of 2.0–2.5 justifies initiating NOAC therapy on the next 
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day (81). Where the INR is >2.5, further considerations of the actual INR value and the half -life of the VKA should be noted before 
switching.  
 
 
Heparin lead-in for VTE therapy 
 
The use of the heparin lead-in for patients with VTE is based on the delay in achieving optimal anticoagulation with warfarin 
therapy and the elevated risk of thrombosis associated with the transition to warfarin use (104). The high level of heterogeneity in 
the study populations, as well as the procedures applied, complicates the process of comparing V TE trials of NOACs. The RE-
COVER (105) and Hokusai-VTE (29) trials both employed heparin lead-ins, lasting a median of 6 and 7 days, respectively. The 
EINSTEIN-PE (31) and EINSTEIN-DVT (32) trials excluded patients who received parenteral anticoagulation for greater than 48 
hours. The AMPLIFY study excluded patients who received more than one day of LMWH or 36 hours of continuous intravenous 
heparin (30). However, 80-90% of patients in the EINSTEIN and AMPLIFY trials received a pre-randomisation dose of parenteral 
heparin. A subgroup analysis of patients who received either rivaroxaban monotherapy or initial parenteral therapy and rivaro xaban 
did not suggest any differences in outcomes (32).   
 
Current recommendations suggest that rivaroxaban and apixaban may be used without the heparin lead-in, while edoxaban and 
dabigatran should include the heparin lead-in phase in the initial and long-term treatment of VTE, reflecting the design of phase III 
trials (89). Expert consensus advises the use of heparin lead-in as per clinical trial protocols, pending further data.  
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Additional considerations 
 
The attitudes and prescribing characteristics of the physician are significant factors in determining the uptake of new agents in 
clinical practice (106). Individual physicians may be reluctant to prescribe NOACs in preference to VKA therapy due to the long 
history of VKA prescribing and the perceived safety and benefits of this therapy, particularly in elderly or frail patients , although 
comparative data do not support this perception (107). However, it is important to combat clinical inertia by reviewing the evidence 
and considering the practical needs and preference of patients.  
 
The simplicity of dosing regimens of the NOACs and the lack of need for routine anticoagulation monitoring suggest that NOACs 
may facilitate earlier and more effective transfer of care from secondary to primary or community care settings. This is part icularly 
the case with VTE management, where primary care transfer is often delayed due to the use of initial parenteral anticoagulation 
(108). 
 
When patients are transferred from the community or the primary care setting to receive an intervention, interruption NOAC therapy 
may be required. This has been described in detail in the EHRA Practical Guide, which should be referred to for a detailed 
overview of the topic in patients with AF (81). Peri-operative bridging with LMWH is generally not necessary when long term oral 
anticoagulants are interrupted for elective procedures in patients with a low or moderate thromboembolic risk and may be 
associated with poorer safety outcomes, including an elevated bleeding risk (109). This strategy is also supported by the results of 
the Dresden NOAC registry, in which major cardiovascular events were consistent in patients regardless of the receipt of bridging 
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therapy during an invasive procedure (110). The expert panel does not recommend routine use of peri-operative LMWH bridging, 
although individualised decisions should be made in this context.  
 
The off-label use of NOACs may take a number of forms, including those that are clinically inappropria te, such as use in patients 
with mechanical prosthetic heart valves (111). The early terminated RE-ALIGN trial suggested that dabigatran was associated with 
an increased risk of stroke, myocardial infarction, thrombosis and bleeding compared to warfarin in patients with mechanical heart 
valves (112). There is no evidence to support NOAC use in patients with mechanical heart valves at present , and this practice 
should be actively discouraged. Use in other indications that have not been explored in extensive trials should not be considered 
without careful consultation. The expert panel advises NOAC use only in situations defined by product labelling, to ensure patient 
safety.  
 
On the other hand, NOACs can safely be used in all types of native valvular heart disease accompanied by AF (113), with the 
exception of mitral stenosis (114). 
 
The justification for dose reduction of NOACs is based on a multitude of phase II and III trials and the support for off -label use of 
NOACs in published guidelines (115). Drug labelling guidelines differ from published guidance (e.g., the EHRA practical guide) and 
therefore disparities can lead to low-dose NOAC use in situations not supported by drug labelling. Off-label dose reductions have 
the potential to lead to undertreatment of patients with AF or VTE. The ORBIT-AF II registry (116) showed that of 5,738 patients 
treated with NOACs, 9.4% were underdosed and 3.4% overdosed compared to product labelling. Off-label dosing was more likely 
in patients who were older, had higher thrombosis risk scores, were of female sex, and had higher bleeding risk scores. The use of 
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NOACs in accordance with the 2016 European Society of Cardiology AF Guideline recommendations (117) has been 
demonstrated to lead to optimal efficacy and safety outcomes, as noted in a post -hoc analysis of the RE-LY trial (118). Therefore, 
current indications and dosing recommendations for NOACs need to be reinforced in practice to avoid unnecessary risk to patients, 
as advised by the expert panel.  
 
At present, NOACs fall into two categories with respect to daily dosing requirements: once-daily agents (edoxaban and 
rivaroxaban), and twice-daily agents (dabigatran and apixaban). When considering the choice of NOAC, one potential factor may 
be the frequency of dosing, particularly in patients with a high pre-existing pill burden. Indeed, where once-daily regimens are used 
in the context of cardiovascular medication, adherence may be improved compared to twice-daily regimens (119). However, it 
should also be considered that all drug dosing regimens rely on good patient adherence, but this is of particular importance with 
once-daily dosing, as missing one dose can lead to a longer period without anticoagulation compared to the same lapse with a 
twice-daily dosing schedule (115). Adherence appears to be maintained slightly better in patients taking once-daily NOACs in 
practice (120,121). Patients most likely to benefit from once-daily dosing include those with an already high pill burden and patients 
with a good level of adherence. For all of the NOACs, dosing should be based on existing guidance, with adherence optimised 
regardless of once- or twice-daily dosing regimens. 
 
Morning or evening dosing is generally considered acceptable for all NOACs. A recent study (122) has shown that evening dosing 
of rivaroxaban is associated with prolonged exposure, better matching the morning hypofibrinolysis observed as part of the 
circadian rhythm. Therefore, evening intake of rivaroxaban may potentially improve safety and efficacy profiles of this drug,  though 
further studies are needed to confirm this potential.  
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For all of the NOACs, with the exception of rivaroxaban, intake may be accompanied with or without food without significantly 
affecting the bioavailability of the drug. In the case of rivaroxaban, the bioavailability of the drug decreases si gnificantly from close 
to 100% to 66% without food (25). Dabigatran, apixaban and edoxaban may represent more convenient options for long -term 
anticoagulation in some patients, due to the fact that these drugs may be taken without considering meal times (124–126). For 
patients requiring anticoagulation through enteral feeding tubes, it should be noted that rivaroxaban can be given as oral so lution or 
via nasogastric tube, but that larger doses require co-administration of a nutritional supplement, while enteral tubes must not be 
distal to the stomach (127,128). Apixaban may be administered as an oral solution or via nasogastric/gastric tubes, and recent data 
suggests that the bioavailability of crushed tablets with or wi thout food is acceptable (125). The large variation in exposure noted 
with crushed dabigatran tablets precludes the use of this NOAC through feeding tubes (128). Recent data suggest that the 
pharmacokinetics of edoxaban tablets crushed and administered either by nasogastric tube or in apple puree is not altered 
(data/manuscript submitted).   
 
 
Conclusion 
 
We have here provided a summary of contemporary evidence regarding NOAC safety, focusing on safety compa red with VKA 
therapy and safety between the NOACs. Although clinical trial data support the use of NOACs as an effective and safe alternative 
to VKA therapy in both AF and VTE contexts, there is a need to consider the individual clinical profile  and risk factors of patients 
prior to NOAC initiation. The role of dose reductions to enhance NOAC safety in certain patient subgroups is becoming clearer. 
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Where data were lacking, we have developed consensus statements to guide contemporary practice. These statements are largely 
consistent with available clinical guidelines, emphasising the complexity of decision-making in patients with AF or VTE, while 
highlighting the emerging clinical issues relating to NOAC safety in practice (table 5).  
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Appendices 
 
 
Table 1. Hierarchy of evidence for the formulation of expert statements (24). 
 
 
Level of evidence Source data 
Level I Meta-analysis of RCTs 
High-quality RCTs 
Level II Controlled studies, without randomisation 
Level III Descriptive studies (comparative, correlation, case-control) 
Level IV Expert opinion or reports from medical bodies/organisations 
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Table 2. Expert statements for patient safety outcomes (combined expert consensus and evidence-based statements). 
CRNM bleeding, clinically-relevant non-major bleeding 
 
Clinical topic Expert statement SOS % expert 
agreement 
Level of 
evidence 
Major/CRNM 
bleeding 
The rates of major bleeding and clinically-relevant non-major bleeding with 
NOACs are favourable compared to VKA therapy in both AF and VTE 
patients. However, basing clinical decision-making on this factor alone is not 
advisable due to the heterogeneity in bleeding risk on an individual patient 
basis. 
Weak - I 
A thorough bleeding risk assessment must be used to guide the identification 
of modifiable risk factors to minimise major bleeding events. 
Strong 100% II 
Intracranial bleeding The use of NOACs in preference to VKA therapy reduces the likelihood of 
intracranial bleeds. 
Strong - I 
A thorough risk factor assessment must be used to identify modifiable risk 
factors for intracranial bleeding and these should be addressed prior to the 
use of any oral anticoagulant.  
Strong - IV 
Gastrointestinal 
bleeding 
A thorough gastrointestinal bleeding risk assessment should be conducted 
before initiating anticoagulation in either AF or VTE patients.  
Weak - IV 
Bleeding mortality NOACs reduce the risk of fatal bleeding compared to warfarin in both AF and 
VTE contexts. However, a multifactorial analysis of bleeding risk, balanced 
Weak 71% IV 
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with stroke risk, should be used to guide therapy, rather than this single factor 
alone.  
Cardiovascular 
mortality 
At present, evidence suggests that NOACs in general should be selected 
over VKA therapy on the basis that they are safer through a reduction in 
cardiovascular mortality alone. 
Weak 71% IV 
Optimisation of cardiovascular risk factors is advised irrespective of 
anticoagulation for AF or VTE. 
Strong 100% IV 
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Table 3. Expert statements for specific patient groups (combined consensus and evidence-based statements). 
 
Clinical topic Expert statement SOS % expert 
agreement 
Level of 
evidence 
Elderly and fragile Elderly patients are at an increased risk of bleeding with anticoagulant 
therapy, but the NOACs (with the exception of dabigatran) demonstrate 
comparable safety in this group compared to the general study population 
suggesting that they are viable anticoagulant choices in VTE and AF patients 
aged ≥75 years. 
Strong - I 
Age alone should only be used to justify dose modifications of NOACs in 
specific cases e.g. dabigatran dose reduction to 110 mg twice daily in 
patients aged >80 years. 
Weak 86% I 
It is advised that dose reduction of NOACs in patients with AF or VTE be 
performed in accordance with published guidance, taking into account factors 
that may increase drug exposure and thereby increase the risk of bleeding. 
Strong - IV 
Patients with active 
cancer 
Consistent with VTE guidelines (134,135), NOACs should only be considered 
in active cancer patients who cannot tolerate LMWH.  
 
(However, recent data suggest that edoxaban is non-inferior to LMWH in 
these patients.) 
Weak 71% IV 
When chronic anticoagulation is needed in patients with active cancer, and Strong 86% I 
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LMWH is not suitable, NOACs are advised as alternative agents to warfarin 
NOAC use in patients with AF and cancer must be based on an appraisal of 
known bleeding and thrombosis risk factors, in addition to potential drug-drug 
interactions.  
Strong 100% IV 
Dose-reduced NOACs are advised in active cancer patients with impaired 
renal function, low body weight and/or advancing age, according to published 
AF guidelines.  
Strong 86% IV 
Patients with renal 
impairment 
Renal function is a key factor in determining drug exposure levels of NOACs 
and it is advised that renal function is routinely assessed prior to NOAC use. 
Strong - III 
NOACs are not advised for use in patients with CrCl <15 ml/min (<30 ml/min 
for dabigatran). 
Strong - III 
Consideration of dose-adjusted NOAC therapy is advised for all patients with 
renal impairment, according to practical guidelines, for the management of 
AF. This may be considered for VTE therapy, but is not advised for 
rivaroxaban or apixaban. 
Strong - IV 
Renal function must be considered in concert with additional risk factors for 
increased drug exposure (low body weight, advancing age) when determining 
the suitability and dose of NOACs. 
Strong - III 
Obese patients There is insufficient evidence to suggest that NOAC dose adjustments are 
justified in obese patients; this practice is not advised.   
Strong 71% IV 
Single stroke risk It should be considered that contemporary guidelines are used and that Strong 86% IV 
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factor (CHA2DS2-
VASc =1 in men, 2 in 
women) 
 
individual patient risk factors should be taken into account in borderline 
instances, where CHA2DS2-VASc = 1 for men, when determining the need for 
anticoagulation with NOACs.   
Where CHA2DS2-VASc = 2 in women, it is advised that anticoagulation is 
initiated, as per published ESC guidelines. 
Strong 86% IV 
Primary vs secondary 
stroke prevention 
NOACs are advised in patients with a previous history of stroke/TIA as they 
have a lower risk of bleeding compared to warfarin therapy. 
Strong - IV 
Patients with an 
increased bleeding 
risk 
Bleeding risk scores may be used to identify modifiable risk factors for 
bleeding and prompt routine review of patients, rather than as tools to select 
suitability for NOAC/VKA use or to justify dose adjustments to NOAC therapy. 
However, individual bleeding risk factor identification is essential and must be 
performed, regardless of the use of these scoring systems.    
Strong 71% IV 
Dual antiplatelet 
therapy 
Dual antiplatelet therapy in combination with NOACs should be minimised to 
avoid excessive bleeding risks, lasting for one month following elective PCI 
and up to six months following acute coronary syndrome management. 
Weak - IV 
Dose reductions of NOACs should be pursued cautiously depending on the 
individual patient bleeding and thromboembolic risk factors. 
Weak - IV 
Incidental VTE In cases of incidental VTE, therapeutic anticoagulation must be considered 
unless there are contraindications to therapy.  
Strong - IV 
 Where incidental VTE is noted in patients already on NOAC therapy, 
diagnostic confirmation and full risk factor assessment is advised to guide 
Strong - IV 
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future anticoagulation therapy.   
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Table 4. Expert statements for practical use of NOACs (combined consensus and evidence-based statements). 
 
Clinical topic Expert statement SOS % expert 
agreement 
Level of 
evidence 
Once daily dosing Once-daily dosing with NOACs should be considered in patients already 
taking a number of medications, although twice-daily dosing may not be 
problematic in patients already on similar regimens. 
Strong 100% IV 
The safety of once-daily dosing relies on optimal patient adherence and it is 
advised that patients are educated on the importance of taking their drug at 
the prescribed frequency and what to do if a dose is missed. 
Strong 100% III 
Either evening or morning intake of once-daily NOACs is considered 
acceptable based on expert consensus; for some patients it may be optimal 
to time drug intake in accordance with concomitant medications to maximise 
adherence. Rivaroxaban may be preferably taken in the evening with food. 
Strong 100% IV 
NOAC administration Edoxaban and apixaban may be safely taken with or without food; dabigatran 
and rivaroxaban should be taken with food due to the risk of gastrointestinal 
upset and poor drug bioavailability, respectively. 
Strong - II 
When NOACs need to be delivered through a feeding tube, dabigatran should 
be avoided. Apixaban may be administered on an empty stomach and 
rivaroxaban may be administered with or without food (a nutritional 
supplement is advised with larger doses). More data are needed on 
Strong - III 
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edoxaban (currently submitted). 
Off-label use Off-label use of NOACs is not generally advised. Strong 100% II 
Off-label dose 
reductions 
Dose-reduced NOAC therapy is advised only in line with current product 
labelling.  
Strong 86% II 
Prescribing 
experience and 
transfer of care 
NOACs can lead to earlier discharge and effective use in the primary 
care/community setting and careful patient evaluation is needed to determine 
those who would benefit the most. 
Strong - IV 
 Specific guidance on NOAC management during transfer of care is essential 
for patients and prescribers- this should be reflected on a local policy level. 
Strong - IV 
 Peri-operative bridging with LMWH is generally not required for patients on 
NOAC therapy, although individual risks of thromboembolism or bleeding 
should be taken into account. 
Strong 86% III 
Switching patients 
from VKA to NOACs 
The decision to switch from VKA therapy to NOAC therapy must be based on 
individual patient factors. 
Strong - IV 
Patients with end stage renal disease should not be switched (<30 mL/min for 
dabigatran, <15 mL/min for other NOACs). 
Strong - IV 
When the decision to switch has been made, INR values should be recorded 
prior to NOAC initiation. A NOAC should be started when the INR is ≤3 for 
rivaroxaban, ≤2.5 for edoxaban, and ≤2 for apixaban and dabigatran. EHRA 
guidance on switching may also be applied.  
Strong - III 
Heparin lead-in for The heparin lead-in (parenteral therapy) must be used for edoxaban and Strong 85% I 
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VTE dabigatran in patients with VTE, but is not necessary for rivaroxaban or 
apixaban.  
The benefits of the heparin lead-in for all NOACs are not established; trial 
regimens should be followed in practice pending further data. 
Weak 71% IV 
Managing acute 
bleeding 
A graduated approach to bleeding management is advised in patients 
prescribed NOACs; specific reversal agents are limited for all NOACs and 
their use is advised for life-threatening or severe bleeding.  
Strong 100% I 
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Table 5. Priority areas for further research regarding NOAC safety 
 
Key area Implications/importance 
Off-label dose reduction in patients at risk 
of high exposure 
If the effect of NOACs is measurable, off-label use may be considered. Off-label dose reductions 
when exposure may be increased are also justifiable. 
Heparin lead-in for all NOACs The role of the heparin lead-in is questionable, as this was largely based on practice prior to 
NOAC introduction in the VTE setting. The value for the lead-in for all NOACs should be explored 
and vice versa. 
NOAC dose adjustment in obese patients Obesity affects a significant proportion of the population and there are limited data on dosing of 
NOACs in this subgroup; obesity may affect drug exposure, leading to suboptimal effects. More 
pharmacokinetic data is warranted. 
Risk factor assessment and treatment In some patient, even ‘weak’ risk factors for poor outcomes (e.g. hypertension) may justify the use 
of NOACs, which have good safety profiles. 
NOAC use in patients with active cancer Chronic LMWH use is not feasible and VKA therapy is associated with poorer prevention of 
recurrent VTE and a significant bleeding risk; more trials of NOACs in this population are needed 
to explore the effects of cancer therapy and physiology on safety. 
Borderline cases or patients with bleeding 
and/or dose reduction risk factors 
In patients with one criterion for dose reduction (e.g. low body weight) the presence of an 
additional bleeding risk factor may justify dose reduction. Data are needed to explore variations in 
exposure in these instances, to justify dose adjustment. 
Bleeding management cost The use of specific bleeding reversal agents may be justified in all cases of significant bleeding- 
costs inhibit this in practice. Cost-effectiveness analyses are justified.  
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